AGENUS INC (AGEN) Current Ratio
- Current ratio · latest quarter: Value 0.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.34× | Current assets / current liabilities. $78.81M ÷ $231.82M ≈ 0.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 78.81M USD | Assets, Current |
| Current obligations | 231.82M USD | Liabilities, Current |
| Cash and equivalents | 18.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 14.72M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 58.98M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 30.07M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $78.81M | $231.82M | $18.74M | (m) | $14.72M | (m) | $58.98M | $30.07M | 0.34× |
| 2026-03-31 | $95.28M | $249.24M | $35.00M | (m) | $6.56M | (m) | $71.08M | $30.19M | 0.38× |
| 2025-12-31 | $133.44M | $323.49M | $3.00M | (m) | $1.83M | (m) | $82.99M | $44.66M | 0.41× |
| 2025-09-30 | $133.95M | $287.13M | $3.46M | (m) | $538.00K | (m) | $85.29M | $10.61M | 0.47× |
| 2025-06-30 | $13.34M | $234.56M | $9.53M | (m) | $709.00K | (m) | $74.40M | $10.72M | 0.06× |
| 2025-03-31 | $23.14M | $208.30M | $18.49M | (m) | $354.00K | (m) | $64.24M | $731.00K | 0.11× |
| 2024-12-31 | $45.57M | $221.40M | $40.44M | (m) | $407.00K | (m) | $61.47M | $2.70M | 0.21× |
| 2024-09-30 | $50.15M | $270.64M | $44.78M | (m) | $207.00K | (m) | $45.90M | $13.40M | 0.19× |
| 2024-06-30 | $100.00M | $270.67M | $93.72M | (m) | $719.00K | (m) | $50.84M | $13.43M | 0.37× |
| 2024-03-31 | $60.35M | $256.00M | $52.86M | (m) | $476.00K | (m) | $50.69M | $13.57M | 0.24× |
| 2023-12-31 | $112.42M | $255.90M | $76.11M | (m) | $25.84M | (m) | $61.45M | $146.00K | 0.44× |
| 2023-09-30 | $125.55M | $198.36M | $106.31M | (m) | $1.03M | (m) | $40.87M | $387.00K | 0.63× |
| 2023-06-30 | $170.74M | $204.07M | $143.21M | (m) | $1.34M | (m) | $52.47M | $622.00K | 0.84× |
| 2023-03-31 | $205.69M | $190.90M | $164.82M | (m) | $1.42M | (m) | $46.77M | $1.02M | 1.08× |
| 2022-12-31 | $213.12M | $188.95M | $178.67M | (m) | $2.74M | (m) | $40.94M | $575.00K | 1.13× |
| 2022-09-30 | $251.43M | $173.07M | $208.35M | (m) | $8.82M | (m) | $39.71M | $13.46M | 1.45× |
| 2022-06-30 | $288.93M | $159.72M | $228.38M | (m) | $18.99M | (m) | $41.00M | $13.70M | 1.81× |
| 2022-03-31 | $290.48M | $163.06M | $247.71M | (m) | $1.29M | (m) | $34.54M | $14.18M | 1.78× |
| 2021-12-31 | $331.97M | $156.94M | $291.93M | (m) | $1.52M | (m) | $30.49M | $728.00K | 2.12× |
| 2021-09-30 | $308.40M | $150.13M | $256.53M | (m) | $21.77M | (m) | $25.12M | $542.00K | 2.05× |
| 2021-06-30 | $92.85M | $168.75M | $73.54M | (m) | $1.44M | (m) | $19.16M | $838.00K | 0.55× |
| 2021-03-31 | $135.66M | $138.37M | $119.37M | (m) | $2.17M | (m) | $19.48M | $1.46M | 0.98× |
| 2020-12-31 | $113.78M | $129.88M | $99.87M | (m) | $1.16M | (m) | $17.02M | $833.00K | 0.88× |
| 2020-09-30 | $125.45M | $146.90M | $114.14M | (m) | $1.41M | (m) | $20.54M | $1.18M | 0.85× |
| 2020-06-30 | $104.76M | $142.27M | $79.17M | (m) | $16.63M | (m) | $20.70M | $1.53M | 0.74× |
| 2020-03-31 | $102.77M | $127.34M | $92.28M | (m) | $2.64M | (m) | $14.75M | $646.00K | 0.81× |
| 2019-12-31 | $86.54M | $122.21M | $61.81M | (m) | $16.29M | (m) | $13.56M | $646.00K | 0.71× |
| 2019-09-30 | $107.19M | $132.95M | $93.27M | (m) | $2.33M | $55.00K | $16.42M | $13.85M | 0.81× |
| 2019-06-30 | $138.94M | $121.74M | $121.72M | (m) | $2.21M | $55.00K | $19.05M | $13.68M | 1.14× |
| 2019-03-31 | $179.12M | $105.51M | $158.31M | (m) | $796.00K | $55.00K | $12.73M | $13.52M | 1.70× |
| 2018-12-31 | $74.81M | $68.06M | $53.05M | (m) | $938.00K | $55.00K | $13.62M | $146.00K | 1.10× |
| 2018-09-30 | $67.64M | $58.19M | $46.17M | (m) | $6.07M | $55.49K | $11.15M | $146.06K | 1.16× |
| 2018-06-30 | $67.70M | $51.32M | $43.16M | (m) | $10.92M | $55.49K | $10.23M | $146.06K | 1.32× |
| 2018-03-31 | $65.19M | $30.16M | $52.35M | (m) | $1.13M | $62.24K | $5.41M | $146.06K | 2.16× |
| 2017-12-31 | $73.55M | $56.44M | $60.19M | (m) | $1.13M | $79.49K | $8.09M | $20.64M | 1.30× |
| 2017-09-30 | $84.34M | $54.41M | $65.08M | (m) | $2.19M | $80.24K | $6.72M | $19.96M | 1.55× |
| 2017-06-30 | $110.69M | $32.91M | $81.83M | (m) | $3.94M | $87.00K | $4.57M | $146.06K | 3.36× |
| 2017-03-31 | $137.95M | $36.35M | $113.86M | (m) | $6.77M | $87.45K | $4.82M | $146.06K | 3.79× |
| 2016-12-31 | $91.31M | $40.85M | $71.45M | (m) | $11.35M | $88.20K | $5.43M | $146.06K | 2.24× |
| 2016-09-30 | $109.53M | $34.85M | $75.44M | (m) | $10.28M | $88.20K | $3.27M | $146.06K | 3.14× |
| 2016-06-30 | $136.07M | $33.06M | $73.40M | (m) | $9.42M | $88.20K | $5.02M | $146.06K | 4.12× |
| 2016-03-31 | $161.61M | $31.26M | $78.33M | (m) | $10.22M | $88.20K | $2.51M | $146.06K | 5.17× |
| 2015-12-31 | $184.10M | $28.93M | $136.70M | (m) | $9.80M | $88.20K | $4.49M | $146.06K | 6.36× |
| 2015-09-30 | $208.94M | $28.29M | $184.14M | (m) | $7.33M | $88.20K | $3.09M | $146.06K | 7.39× |
| 2015-06-30 | $146.28M | $25.32M | $124.66M | (m) | $4.11M | $88.20K | $2.66M | $146.06K | 5.78× |
| 2015-03-31 | $85.15M | $21.00M | $79.30M | (m) | $2.53M | $88.20K | $3.97M | $423.84K | 4.06× |
| 2014-12-31 | $42.67M | $9.23M | $25.71M | (m) | $463.01K | $95.70K | $1.71M | $1.26M | 4.62× |
| 2014-09-30 | $55.22M | $15.61M | $38.39M | (m) | $0.00 | $95.70K | $2.26M | $6.72M | 3.54× |
| 2014-06-30 | $67.03M | $18.57M | $48.27M | (m) | $0.00 | $95.70K | $929.90K | $7.43M | 3.61× |
| 2014-03-31 | $75.26M | $14.37M | $73.49M | (m) | $0.00 | (m) | $1.68M | $2.87M | 5.24× |
| 2013-12-31 | $28.17M | $10.30M | $27.35M | (m) | $1.20K | $0.00 | $834.74K | $3.52M | 2.74× |
| 2013-09-30 | $30.88M | $9.65M | $30.20M | (m) | $1.13K | $3.27K | $365.35K | $3.26M | 3.20× |
| 2013-06-30 | $14.45M | $7.18M | $13.44M | (m) | $202.49K | $4.02K | $421.78K | $2.43M | 2.01× |
| 2013-03-31 | $18.35M | $5.78M | $17.21M | (m) | $163.73K | $16.02K | $581.55K | $201.48K | 3.18× |
| 2012-12-31 | $22.61M | $4.81M | $21.47M | (m) | $552.33K | $16.02K | $634.75K | $204.09K | 4.70× |
| 2012-09-30 | $25.79M | $4.83M | $24.76M | (m) | $369.06K | $16.02K | $467.83K | $210.47K | 5.34× |
| 2012-06-30 | $26.48M | $4.59M | $25.46M | (m) | $92.29K | $18.57K | $632.07K | $212.47K | 5.77× |
| 2012-03-31 | $25.95M | $5.51M | $24.59M | (m) | $58.72K | $18.57K | $340.45K | $203.03K | 4.71× |
| 2011-12-31 | $12.00M | $4.75M | $10.75M | (m) | $0.00 | $20.07K | $807.93K | $197.68K | 2.53× |
| 2011-09-30 | $15.99M | $5.87M | $14.73M | (m) | $0.00 | $26.43K | $504.14K | $196.20K | 2.73× |
| 2011-06-30 | $13.30M | $4.81M | $12.02M | (m) | $188.00 | $26.43K | $340.03K | $146.06K | 2.77× |
| 2010-12-31 | $20.85M | $5.42M | $19.78M | (m) | $35.00K | $26.43K | $698.55K | $146.06K | 3.85× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |